Overview

Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis

Status:
Completed
Trial end date:
2017-07-27
Target enrollment:
Participant gender:
Summary
The purpose of the study is to demonstrate the efficacy of vonoprazan (TAK-438) versus lansoprazole in the treatment of erosive esophagitis classified as Los Angeles (LA) classification grades A to D at Week 8.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Dexlansoprazole
Lansoprazole